Mallinckrodt (MNK) Tops Q4 EPS by 32c, Beats on Revenues; Offers FY18 EPS Guidance Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/28/2026

1. SPY
2. AKAM
3. COST
4. META
5. NVDA
6. ZS
7. AWK
8. DRI
9. ULS
10. VEON

Go back to Mallinckrodt (MNK) Tops Q4 EPS by 32c, Beats on Revenues; Offers FY18 EPS Guidance Below Consensus

Mallinckrodt (MNK) Receives FDA Acceptance of Stannsoporfin NDA Filing

February 23, 2018 6:56 AM EST

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) seeking approval of its... More